Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglycemia. In fact, they have been found to be effective for weight loss in patients with obesity with and without diabetes. They are now the preferred drugs to add to the regimen when oral metformin by itself is not enough to meet the patient’s hemoglobin A1c goal.
CITATION STYLE
Nachawi, N., Rao, P. P., & Makin, V. (2022). The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleveland Clinic Journal of Medicine, 89(8), 457–464. https://doi.org/10.3949/ccjm.89a.21110
Mendeley helps you to discover research relevant for your work.